表紙
市場調查報告書

輔助人工心臟 (VAD)、全人工心臟 (TAH)的全球市場:產品、流通管道、地區資料 - 分析與預測 (2019-2023年)

Global Ventricular Assist Devices and Total Artificial Heart Market: Focus on Products, Distribution Channels, Regional, Data - Analysis and Forecast, 2019-2023

出版商 BIS Research Inc. 商品編碼 891203
出版日期 內容資訊 英文 153 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
輔助人工心臟 (VAD)、全人工心臟 (TAH)的全球市場:產品、流通管道、地區資料 - 分析與預測 (2019-2023年) Global Ventricular Assist Devices and Total Artificial Heart Market: Focus on Products, Distribution Channels, Regional, Data - Analysis and Forecast, 2019-2023
出版日期: 2019年07月04日內容資訊: 英文 153 Pages
簡介

全球輔助人工心臟 (VAD)、全人工心臟 (TAH) 市場到2023年前預計將達到27億美元的規模。

本報告提供全球輔助人工心臟 (VAD)、全人工心臟 (TAH) 市場調查,產品定義,市場概要,對市場成長的各種影響因素及市場機會分析,各市場區隔、地區/主要國家等各種區分的趨勢與市場規模的變化與預測,競爭環境,及主要企業的簡介等系統性資訊。

摘要整理

第1章 產品定義

第2章 調查範圍

第3章 調查手法

第4章 產業分析

  • 產業結構
  • 價值鏈分析
  • 法律規範
  • 專利分析

第5章 競爭情形

  • 供應商的佔有率分析
  • 主要的發展、策略

第6章 市場動態

  • 市場成長的促進因素
  • 市場成長的阻礙因素
  • 市場機會

第7章 全球輔助人工心臟 (VAD)、全人工心臟 (TAH) 市場:各產品

  • 概要
  • 前提條件、限制事項
  • 輔助人工心臟 (VAD)
  • 全人工心臟 (TAH)

第8章 全球輔助人工心臟 (VAD)、全人工心臟 (TAH) 市場:各流通管道

  • 概要
  • 醫院
  • 心臟診所

第9章 全球輔助人工心臟 (VAD)、全人工心臟 (TAH) 市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第10章 企業簡介

  • 概要
  • Abbott Laboratories
  • ABIOMED
  • Berlin Heart
  • BiVACOR
  • CARMAT
  • Jarvik Heart Inc.
  • Sun Medical Technology Research Institute, Inc.
  • LivaNova PLC
  • Medtronic PLC
  • SynCardia Systems, LLC
目錄
Product Code: BH133A

"Global Ventricular Assist Devices and Artificial Heart Systems Market to Reach $2.70 Billion by 2023, Reports BIS Research."

Key Questions Answered in the Report:

  • What are the key features of ventricular assist devices and artificial heart systems which makes them suitable for the end-stage heart failure patients?
  • What is the industry structure of the global ventricular assist devices and artificial heart systems market?
  • How many patents are currently active in the global ventricular assist devices and artificial heart systems market?
  • How does the value chain function in the global ventricular assist devices and artificial heart systems market?
  • What are the key development strategies which are implemented by the key players to stand out in the market?
  • How did the ventricular assist devices and artificial heart systems market evolve and what is its scope in the future?
  • What are the major market drivers, challenges, and opportunities in the global ventricular assist devices and artificial heart systems?
  • What are the leading companies dominating the global ventricular assist devices and artificial heart systems market?
  • What are investors' perceptions about the global ventricular assist devices and artificial heart systems market? Also, what is the reimbursement scenario of the market?
  • What are the regulations pertaining to the global ventricular assist devices and artificial heart systems market? What are the initiatives implemented by different government bodies to overcome the shortage of organ donors?
  • What was the market value of the leading segments and sub-segments of the global ventricular assist devices and artificial heart systems market?
  • How is each segment of the global ventricular assist devices and artificial heart systems market expected to grow during the forecast period and what is the revenue expected to be generated by each of the segments by the end of 2023?

Global Ventricular Assist Devices and Artificial Heart Systems Market Forecast, 2019-2023

The global ventricular assist devices and artificial heart systems market was estimated at $2.20 billion in 2018 and is anticipated to reach $2.70 billion by 2023. In 2018, ventricular assist devices contributed about 90% of market share.

Heart attack and stroke have resulted in the increasing mortality rate worldwide as per the World Health Organization (WHO). In 2016, it was estimated that about 17.9 million people died due to CVDs, which represented about 31% of the global mortality rate. Heart attack and stroke have contributed to the growing number of individuals suffering from CVDs. According to the WHO, stroke or cerebrovascular accident are the second leading cause of death worldwide.

The prevalence of heart failure has been estimated to increase during the recent years, due to the changing lifestyle, high levels of alcohol and tobacco consumption, and unhealthy diet plan. The ventricular assist devices and artificial heart systems are two key products used for mechanical circulatory support in end-stage heart failure patients. The market demand for these devices has emerged due to lack of organ donors and high incidence of heart failure cases worldwide.

Expert Quote on the Global Ventricular Assist Devices and Artificial Heart Systems Market

"North America is currently the leading contributor in the global ventricular assist devices and artificial heart systems market. The North America ventricular assist devices and artificial heart systems market was valued at $1.42 billion in 2018. Factors such as increasing incidence of heart failure cases, rise in aging population, pediatric heart failure cases, changing reimbursement policies, and established healthcare infrastructure are driving the growth of the ventricular assist devices and artificial heart systems market in North America."

Scope of the Market Intelligence on Global Ventricular Assist Devices and Artificial Heart Systems Market

The purpose of the study is to gain a holistic view of the global ventricular assist devices and artificial heart systems market in terms of various factors influencing it such as recent trends and technological advancements of the market. The scope of this report is centered upon conducting a detailed study of the mechanical circulatory assist devices which have the potential to help the end-stage heart failure patients.

The global ventricular assist devices and artificial heart systems market is segmented into three types: product type, distribution channel, and region. The global market value was estimated using these three different approaches, which were validated with one another. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions.

Market Segmentation

The ventricular assist devices market is further sub-segmented into left-, right-, and bi-ventricular assist devices. The left-ventricular assist device segment contributed maximum to the product revenue contributing 60% of share in 2018. The product launches in pipeline are expected to increase the CAGR of the market in the coming future.

Based on distribution channel, hospitals occupied higher market share contributing more than 90% to the market revenue as of 2018. In 2018, cardiology clinics showed a significant growth in the market with a CAGR of 4.19%, with the rising number of patient reference to these clinics by the VAD centers.

The global ventricular assist devices and artificial heart systems market is segmented by the geographical regions into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). The RoW region comprises Latin America, Middle East, and Africa. North America is the leading contributor to the global ventricular assist devices and artificial heart systems market with a contribution of about 64.5% of the total market share in 2018. The North America market is also expected to grow at a CAGR of 3.26% in the forecast period 2019-2023. The global ventricular assist devices and artificial heart systems market is majorly dominated by the U.S. and the European players. However, several emerging countries of Asia-Pacific and Latin America displayed high potential to witness robust growth rate during the period. The emerging countries have low access to the ventricular assist devices and artificial heart systems due to cost constraints in the market.

Key Companies Operating in the Global Ventricular Assist Devices and Artificial Heart Systems Market

The key players who have significant contributions to the global ventricular assist devices and artificial heart systems market are Abbott Laboratories, Medtronic PLC, LivaNova PLC, Abiomed, SynCardia Systems, LLC, Jarvik Heart Inc., Berlin Heart, BiVACOR, among others.

Table of Contents

Executive Summary

1. Product Definition

  • 1.1. Ventricular Assist Devices
  • 1.2. Total Artificial Heart

2. Scope of the Report

3. Research Methodology

  • 3.1. Research Methodology

4. Industry Analysis

  • 4.1. Industry Structure
  • 4.2. Value Chain Analysis
  • 4.3. Regulatory Framework
    • 4.3.1. Regulatory Framework in America
    • 4.3.2. Regulatory Framework in Europe
    • 4.3.1. Regulatory Framework in Asia-Pacific
  • 4.4. Patent Analysis

5. Competitive Landscape

  • 5.1. Vendor Share Analysis
  • 5.2. Key Developments and Strategies
    • 5.2.1. Funding
    • 5.2.2. Product Approvals
    • 5.2.3. Mergers and Acquisitions
    • 5.2.4. Agreements, Partnerships, and Collaborations
    • 5.2.5. Other Strategies

6. Market Dynamics

  • 6.1. Market Drivers
    • 6.1.1. Growing Geriatric Population
    • 6.1.2. Rising Incidence of Lifestyle Diseases
    • 6.1.3. Increasing Need of Organ Transplantation and Deadly Shortage of Available Donors
    • 6.1.4. Persistent Support from Government and Non-Governmental Organizations
    • 6.1.5. Technological Advancements and Increased R&D Expenditure
  • 6.2. Challenges
    • 6.2.1. Risks of Device Malfunction and Other Related Concerns
    • 6.2.2. Immune Barrier to Artificial Organ
    • 6.2.3. Stringent Regulation and Poor Reimbursement Coverage
    • 6.2.4. Exorbitant Cost of Product
  • 6.3. Opportunities
    • 6.3.1. Application of Advanced Biomaterials in Artificial Organs
    • 6.3.2. Organ-on-chips Technology

7. Global Ventricular Assist Devices and Total Artificial Heart Market (Product)

  • 7.1. Overview
  • 7.2. Assumptions and Limitations
  • 7.3. Ventricular Assist Devices
    • 7.3.1. Components of a VAD
    • 7.3.2. Types of VAD
    • 7.3.3. Timeline
    • 7.3.4. Left Ventricular Assist Device
    • 7.3.5. Right Ventricular Assist Device
    • 7.3.6. Bi-Ventricular Assist Device
  • 7.4. Total Artificial Heart
    • 7.4.1. Timeline

8. Global Ventricular Assist Devices and Total Artificial Heart Market (Distribution Channels)

  • 8.1. Overview
  • 8.2. Hospitals
  • 8.3. Cardiology Clinics

9. Global Ventricular Assist Devices and Total Artificial Heart Market (by Region)

  • 9.1. Overview
    • 9.1.1. Analysis of Growth Potential of Different Countries
  • 9.2. North America
    • 9.2.1. The U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. The U.K.
    • 9.3.3. France
    • 9.3.4. Italy
    • 9.3.5. Sweden
  • 9.4. Asia-Pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. Australia
    • 9.4.4. India
  • 9.5. Rest-of-the-World
    • 9.5.1. Latin America
    • 9.5.2. Middle East and Africa

10. Company Profiles

  • 10.1. Overview
  • 10.2. Abbott Laboratories
    • 10.2.1. Overview
    • 10.2.2. Role of Abbott Laboratories in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.2.3. Financials
    • 10.2.4. Key Developments
    • 10.2.5. SWOT Analysis
  • 10.3. ABIOMED
    • 10.3.1. Overview
    • 10.3.2. Role of ABIOMED in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.3.3. Financials
    • 10.3.4. Key Developments
    • 10.3.5. SWOT Analysis
  • 10.4. Berlin Heart
    • 10.4.1. Overview
    • 10.4.2. Role of Berlin Heart in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.4.3. Key Developments
    • 10.4.4. SWOT Analysis
  • 10.5. BiVACOR
    • 10.5.1. Overview
    • 10.5.2. Role of BiVACOR in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.5.3. Key Development
    • 10.5.4. SWOT Analysis
  • 10.6. CARMAT
    • 10.6.1. Overview
    • 10.6.2. Role of CARMAT in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.6.3. Key Developments
    • 10.6.4. SWOT Analysis
  • 10.7. Jarvik Heart Inc.
    • 10.7.1. Overview
    • 10.7.2. Role of Jarvik Heart Inc. in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.7.3. SWOT Analysis
  • 10.8. Sun Medical Technology Research Institute, Inc.
    • 10.8.1. Overview
    • 10.8.2. Role of Sun Medical Technology Research Institute in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.8.3. Key Developments
    • 10.8.4. SWOT Analysis
  • 10.9. LivaNova PLC
    • 10.9.1. Overview
    • 10.9.2. Role of LivaNova PLC in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.9.3. Key Developments
    • 10.9.4. Financials
      • 10.9.4.1. Key Insights About Financial Health of the Company
    • 10.9.5. SWOT Analysis
  • 10.10. Medtronic PLC
    • 10.10.1. Overview
    • 10.10.2. Role of Medtronic PLC in the Global Ventricular Assist Devices and Total Artificial Heart Market
    • 10.10.3. Financials
      • 10.10.3.1. Key Insights about Financial Health of the Company
    • 10.10.4. SWOT Analysis
  • 10.11 SynCardia Systems, LLC
    • 10.11.1. Overview
    • 10.11.2. Role of Syncardia Systems, LLC in the Ventricular Assist Devices and Total Artificial Heart Market
    • 10.11.3. Key Developments
    • 10.11.4. SWOT Analysis

List of Tables

  • Table 4.1: Regulatory Authorities/Associations/Consortiums for Medical Devices in America
  • Table 4.2: Regulatory Authorities/Associations/Consortiums for Medical Devices in Europe
  • Table 4.3: Regulatory Authorities/Associations/Consortiums for Medical Devices in Asia-Pacific
  • Table 6.1: Percentage of Total Regional Population Aged 65 Years: 2015 & 2030
  • Table 6.2: Contribution of Risk Factors to Lifestyle Diseases (Percentage of Individual Population Attributable Fraction)
  • Table 6.3: Disease Burden Due to Common Lifestyle Diseases Across Different Regions (2016)
  • Table 6.4: Funding Initiatives by Private and Public Companies
  • Table 6.5: Post-Operational Consequences of SynCardia TAH Implantation
  • Table 6.6: Post-Operational Consequences of Total Artificial Heart (TAH) Implantation
  • Table 7.1: Timeline- Ventricular Assist Devices
  • Table 7.2: Timeline- Total Artificial Heart

List of Figures

  • Figure 1: Evolution of VAD and Artificial Heart
  • Figure 2: Market Statistics
  • Figure 3: Impact of Market Drivers and Market Restraints (2018)
  • Figure 4: Global VAD and TAH Market Size, By Product, 2018
  • Figure 5: Share of Key Strategies and Development, January 2014-March 2019
  • Figure 6: Market Share Analysis for the Global Ventricular Assist Devices and Total Artificial Heart Market, 2018
  • Figure 2.1: Global Ventricular Assist Devices and Total Artificial Heart: Market Segmentation
  • Figure 3.1: Ventricular Assist Devices and Total Artificial Heart Market Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Data Triangulation
  • Figure 3.5: Bottom-Up Approach (Segment-wise Analysis)
  • Figure 3.6: Assumptions and Limitations
  • Figure 3.7: Factors Considered for Data Prediction and Modeling
  • Figure 4.1: Value Analysis of Ventricular Assist Devices and Total Artificial Heart Market
  • Figure 4.2: Patent Analysis for the Global Ventricular Assist Devices and Total Artificial Heart Market
  • Figure 4.3: Patent Timeline in the Global Ventricular Assist Devices and Total Artificial Heart Market
  • Figure 5.1: Competitive Landscape- Global Ventricular Assist Devices and Total Artificial Heart Market
  • Figure 5.2: Market Share Analysis for the Global Ventricular Assist Devices and Total Artificial Heart Market, 2018
  • Figure 5.3: Market Share Analysis for the Global Ventricular Assist Devices Market, 2018
  • Figure 5.4: Market Share Analysis for the Global Total Artificial Heart Market, 2018
  • Figure 5.5: Share of Key Developments and Strategies, January 2014-March 2019
  • Figure 5.6: Funding Activities Share (by Companies), January 2014-February 2019
  • Figure 5.7: Product Approval Share (by Companies), January 2014-February 2019
  • Figure 6.1: Projected Global Geriatric Population Aged 60 Years (in billion), 1900-2100
  • Figure 6.2: Number of Donors Recovered and Patients Waiting at the Year-end VS Number of Transplants Performed (2010-2017)
  • Figure 7.1: Global VAD and TAH Market, by Product, Market Share 2018
  • Figure 7.2: Global Left Ventricular Assist Devices Market, 2018-2023
  • Figure 7.3: Global Right Ventricular Assist Device Market, 2018-2023
  • Figure 7.4: Global Bi-Ventricular Assist Devices Market, 2018-2023
  • Figure 7.5: Mechanism of Action of TAH
  • Figure 7.6: Key Points about AbioCor
  • Figure 7.7: Global Total Artificial Heart Market, 2018-2023
  • Figure 7.8: Sales of SynCardia System, LLC's TAH (by Volume), 2009-2023
  • Figure 8.1: Global Ventricular Assist Devices and Total Artificial Heart Market, by Distribution Channel, Market Share 2018
  • Figure 8.2: Hospitals in the Global Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 8.3: Cardiology Clinics in the Global Ventricular Assist Devices and Total Artificial Heart Market, 2018-2028
  • Figure 9.1: Global Ventricular Assist Device and Total Artificial Heart Market by Region, Market Share, 2018
  • Figure 9.2: North America: Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 9.3: North America: Market Dynamics
  • Figure 9.4: Number of Donors Recovered and Transplants Performed per Year VS Patients Waiting at the Year End
  • Figure 9.5: Europe: Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 9.6: Europe: Market Dynamics
  • Figure 9.7: Asia-Pacific: Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 9.8: Asia-Pacific: Market Dynamics
  • Figure 9.9: Rest-of-the-World: Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 9.10: Rest-of-the-World: Market Dynamics
  • Figure 9.11: Latin-America: Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 9.12: Middle-East and Africa: Ventricular Assist Devices and Total Artificial Heart Market, 2018-2023
  • Figure 10.1: Total Number of Companies Profiled
  • Figure 10.2: Abbott Laboratories: Overall Financials, 2016-2018
  • Figure 10.3: Abbott Laboratories, By Segment, 2016-2018
  • Figure 10.4: Abbott Laboratories, By Region, 2016-2018
  • Figure 10.5: Abbott Laboratories: SWOT Analysis
  • Figure 10.6: ABIOMED: Overall Financials, 2016-2018
  • Figure 10.7: ABIOMED, By Segment, 2016-2018
  • Figure 10.8: ABIOMED, R&D Expenditure, 2017-2018
  • Figure 10.9: ABIOMED: SWOT Analysis
  • Figure 10.10: Berlin Heart: SWOT Analysis
  • Figure 10.11: BiVACOR: SWOT Analysis
  • Figure 10.12: CARMAT: SWOT Analysis
  • Figure 10.13: Jarvik Heart Inc.: SWOT Analysis
  • Figure 10.14: Sun Medical Technology Research Institute Inc.: SWOT Analysis
  • Figure 10.15: LivaNova PLC: Overall Product Portfolio
  • Figure 10.16: LivaNova PLC: Overall Financials, 2016-2018
  • Figure 10.17: LivaNova PLC (by Segment), 2016-2018
  • Figure 10.18: LivaNova PLC: Revenue (by Region), 2016-2018
  • Figure 10.19: LivaNova PLC: Revenue for Advanced Circulatory Support (by Region), 2016-2018
  • Figure 10.20: LivaNova PLC: R&D Expenditure, 2016-2018
  • Figure 10.21: LivaNova PLC: SWOT Analysis
  • Figure 10.22: Medtronic PLC: Overall Financials, 2016-2018
  • Figure 10.23: Medtronic PLC: Revenue (by Segment), 2016-2018
  • Figure 10.24: Medtronic PLC: Revenue (by Region), 2016-2018
  • Figure 10.25: Medtronic PLC: R&D Expenditure
  • Figure 10.26: Medtronic PLC: SWOT Analysis
  • Figure 10.27: SynCardia Systems, LLC Product Portfolio for Ventricular Assist Devices and Total Artificial Heart Market
  • Figure 10.28: SynCardia Systems, LLC: SWOT Analysis
Back to Top